Global /Taiwan /Healthcare /Medical Care Facilities /6879

TCI GENE Inc.

6879

• TPEX: 6879 • Delayed

37.00TWD -3.7%

1.17 USD

As of 6 June 2026, TCI GENE Inc. has a market cap of $31.12M USD, ranking #34001 globally and #2093 in Taiwan. It ranks #3071 in the Healthcare sector, and #372 in the Medical Care Facilities industry.

Global Rank

34001

Country Rank

2093

Sector Rank

3071

Industry Rank

372

Key Stats

Market Cap

$31.12MUSD

978.96M TWD

Enterprise Value

$5.64MUSD

178.21M TWD

Revenue (TTM)

$8.7MUSD

273.61M TWD

EBITDA (TTM)

$842.21KUSD

26.61M TWD

Net Income (TTM)

$1.29MUSD

40.57M TWD

EBITDA Margin

9.7%

Profit Margin

15%

PE Ratio

24.3

PS Ratio

3.6

PB Ratio

1.1

EV/EBITDA

7.3

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Medical Care Facilities

Founded

2011

Website

tci-gene.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3.7%	-6.3%	3.9%	-1.3%	-5.1%	4.2%	-20%	-70%	-63%

News

Markets

Exchange	Ticker	Price	Quotes
Taipei Exchange (TPEX) MIC: ROCO PRIMARY	6879 大江基因醫學股份有限公司 Ordinary Shares ISIN: TW0006879000 Shares Out.: Shares Outstanding: 26.459M¹ Shares Float: 12.448M² TV: TradingView: TPEX: 6879 SA: Stock Analysis: TPEX: 6879 YF: Yahoo Finance: 6879.TWO GF: Google Finance: TPEX: 6879 BA: Barron's: 6879 MS: Morningstar: ROCO: 6879	37.00 TWD	TV: TradingView: TPEX: 6879 SA: Stock Analysis: TPEX: 6879 YF: Yahoo Finance: 6879.TWO GF: Google Finance: TPEX: 6879 BA: Barron's: 6879 MS: Morningstar: ROCO: 6879

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About TCI GENE Inc.

TCI GENE Inc., together with its subsidiaries, provides genetic testing and assessment services in Taiwan and Mainland China. It operates through Inspection and Consumable Products segments. The company offers memory, anti-aging, health management, child growth and development, nutritional metabolism and absorption, OB weight management, and SC skin management genetic testing; gut microbiota testing; and LDT cardiovascular drug gene testing services. It also provides precision prediction and personalized health management plans; and adipose-derived mesenchymal stem cells, natural killer immune cells, and immune cell storage programs. In addition, the company manufactures and sells testing reagents, health food, and beauty products; and health and nutritional supplements. TCI GENE Inc. was founded in 2011 and is based in Taipei, Taiwan.

Similar Companies

Industry: Medical Care Facilities (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
Universal Vision Biotechnology Co., Ltd. TPEX: 3218	$374.38M 11.78B TWD 1K%	11.3	Taiwan
Qing Song Health Co.,Ltd. TWSE: 6931	$101.68M 3.2B TWD 227%	34.8	Taiwan
aetherAI Co., Ltd. TPEX: 7803	$87.57M 2.75B TWD 181%	-	Taiwan
Sunny Pharmtech Inc. TPEX: 6676	$66.0M 2.08B TWD 112%	-	Taiwan
Meribank Biotech Co., Ltd. TPEX: 4724	$41.95M 1.32B TWD 35%	-	Taiwan
Genetics Generation Advancement Corp. TPEX: 4160	$37.08M 1.17B TWD 19%	54.6	Taiwan

Industry: Medical Care Facilities (Global)

Name	Market Cap (USD) diff.	PE	Country
International Holding Company PJSC ADX: IHC	$232.18B 852.82B AED 746K%	44.1	United Arab Emirates
HCA Healthcare, Inc. NYSE: HCA	$96.73B 311K%	14.9	United States
Fresenius SE & Co. KGaA XETRA: FRE	$26.68B 22.97B EUR 86K%	15.0	Germany
Koninklijke Philips N.V. AMS: PHIA	$25.58B 22.02B EUR 82K%	24.9	Netherlands
Dr. Sulaiman Al Habib Medical Services Group Co. TADAWUL: 4013	$22.48B 84.42B SAR 72K%	35.2	Saudi Arabia
Labcorp Holdings Inc. NYSE: LH	$21.13B 68K%	24.6	United States

chevron_leftBack